![Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial](https://ilmiodiabete.com/wp-content/uploads/2020/12/Novo_Nordisk_Logo.jpg)
Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
![Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial](https://i0.wp.com/ilmiodiabete.com/wp-content/uploads/2020/12/Novo_Nordisk_Logo.jpg?resize=2000%2C1200&ssl=1)
Il mio diabete #ADA2021 Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
![Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire](https://mms.businesswire.com/media/20191118005269/en/757140/23/4124560_NN_m_2c_RGB_large.jpg)
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire
![Amal Chalfoun nuovo Clinical, Medical and Regulatory Director di Novo Nordisk Italia - Tecnomedicina Amal Chalfoun nuovo Clinical, Medical and Regulatory Director di Novo Nordisk Italia - Tecnomedicina](https://www.tecnomedicina.it/wp-content/uploads/2020/10/amal__002_.jpg)
Amal Chalfoun nuovo Clinical, Medical and Regulatory Director di Novo Nordisk Italia - Tecnomedicina
![Accordo tra Novo Nordisk e Microsoft per accelerare la scoperta e lo sviluppo di farmaci con big data e AI - AboutPharma Accordo tra Novo Nordisk e Microsoft per accelerare la scoperta e lo sviluppo di farmaci con big data e AI - AboutPharma](http://www.aboutpharma.com/wp-content/uploads/2022/09/shutterstock_1739958698-e1663064716347.jpg)